CDK4 and cancer: In cancer cells that have overactive CDK4/6-cyclin D1 activity and a functional Rb protein, CDK4/6 inhibitors block Rb phosphorylation, preventing its deactivation, and leading to G1 cell-cycle arrest or senescence [44].